Objective. The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM.
Introduction
The idiopathic inflammatory myopathies are a group of acquired, heterogeneous, systemic CTDs that include adult DM and PM and JDM. Currently, there are no US Food and Drug Administration-approved therapies based on randomized controlled trials. Rituximab, a B celldepleting agent, has been increasingly used in autoimmune diseases, given the crucial role of B cells in the initiation and propagation of the immune response. Likewise, many retrospective case reports and series have evaluated the use of rituximab in myositis in the past 10 years, including the treatment of the cutaneous features of DM [15] . One open-label, uncontrolled trial of seven DM patients suggested that both skin and muscle disease improved in adult DM [4] , whereas another openlabel uncontrolled trial of eight adult DM patients failed to show a response in severe skin disease after rituximab treatment [6] . Two patients with JDM improved in a case report, and a single-centre retrospective review of JDM patients noted that 75% (9/12) had improvement in cutaneous or muscular manifestations [1, 7] . The Rituximab in Myositis (RIM) Trial allowed the opportunity to evaluate the safety and efficacy of rituximab in treating the rash of DM in both adults and children in a prospective fashion, where the features of myositis were assessed using a validated measure of disease activity [8] .
Methods

Study subjects
The RIM Trial included 200 subjects with refractory myositis (76 PM, 76 adult DM and 48 JDM), who were randomized to receive rituximab early (drug at weeks 0/1, placebo at weeks 8/9) or rituximab late arms (placebo at weeks 0/1, drug at weeks 8/9), such that all subjects received study drug. We used 72 of the 76 adult DM and 48 JDM patients for analysis in this study. They were followed for 44 weeks (14 visits) , and cutaneous disease activity was assessed at several time points: week 0, 4, 8, 12, 16, 20, 24 , 38, 32, 36 and 44. Rituximab dosing was based on the patient's body surface area; children with a body surface area 41.5 m 2 received 575 mg/m 2 at each infusion, and adults and children with a body surface area >1.5 m 2 received 750 mg/m 2 up to 1 g/infusion. The glucocorticoid dose was held constant, without reduction, until week 16, and i.v. glucocorticoids were not allowed at the time of any study medication infusion. Further details of the RIM Trial are published [8] . University of Pittsburgh Institutional Review Board approval and patient consents were obtained for the study.
Cutaneous disease activity assessment
At all 14 visits, cutaneous clinical disease activity was assessed using the Myositis Disease Activity Assessment Tool (MDAAT) [9] . The MDAAT is a reliable and validated outcome measure in myositis, which has been used in multiple clinical trials [914] . It includes a physician assessment of various cutaneous rashes of adult DM and JDM as well as the grading of cutaneous disease activity measure on a 10 cm visual analog scale (VAS). The following variables were assessed longitudinally on all RIM Trial subjects using the MDAAT: cutaneous ulceration, erythroderma, panniculitis, erythematous rashes with or without secondary changes of erosions, necrosis or vesiculobullous lesions, heliotrope rash, Gottron papules or sign, periungal capillary changes, alopecia (diffuse or focal, patchy with erythema) and mechanics hands. The grading of each of these DM-associated cutaneous clinical features at each trial visit was reported as follows: NA indicates cannot be assessed; 0 indicates not present in the last 4 weeks; 1 indicates improvement in the previous 4 weeks; 2 indicates the rash as unchanged in the previous 4 weeks; 3 refers to worsening over the last 4 weeks; and 4 indicates the new onset of that specific feature in the last 4 weeks. In addition, the global cutaneous disease activity over the past 4 weeks was assessed using the 10 cm VAS at each visit, with a score of 0 indicating no active cutaneous disease and 10 being severe active cutaneous disease. All investigators in the RIM Trial received specialized training along with a glossary and key on assessing cutaneous and other organ system involvement using the MDAAT [15] .
Cutaneous damage assessment
A validated myositis damage assessment tool, termed the Myositis Damage Index (MDI), was also assessed in the RIM Trial at weeks 0 and 44 [10, 11, 13] . The MDI variables that were assessed included calcinosis, alopecia (due to damage), cutaneous scarring or atrophy, poikiloderma and lipodystrophy. Each of these cutaneous damage variables above was assessed as follows: NA indicates cannot be assessed; 0 indicates the item has never been present; and 1 indicates the presence of one of the aforementioned damage variables that has been present for at least 6 months. Similar to the MDAAT, the MDI also assessed overall cutaneous damage using a 10 cm VAS, with 0 indicating no evidence of cutaneous damage and 10 noting severe evidence of cutaneous damage according to the examining physician.
Statistical analysis
Descriptive statistics were performed on subject demographics, key clinical features and baseline cutaneous features of disease activity and damage in the adult DM, JDM and combined cohorts. The MDAAT and MDI variables were analysed for adult DM and JDM separately and for the combined cohort. Changes in the frequency of various cutaneous variables of disease activity and damage were assessed at the last visit after rituximab and compared with the baseline (pre-rituximab) finding using the 2 test (or Fisher's exact test). In addition, the VAS score of cutaneous disease activity and damage was assessed at the last trial visit after rituximab and likewise compared with the baseline (pre-rituximab) finding using Student's paired t-test (before and after). The baseline for all of the above analyses was considered as week 0 for the rituximab early subset and week 8 for the rituximab late subjects, such that the findings were determined as the weeks post-rituximab (i. 
Results
Baseline characteristics of JDM and DM subjects
The characteristics of the full cohort of RIM Trial subjects have been described previously [8] . The clinical characteristics of the adult DM and JDM patients are specifically listed in The most common myositis-specific autoantibodies in the adult DM patients included anti-Mi-2 (28%) and antisynthetase (21%), whereas the JDM subjects possessed anti-NXP2 (33%) and anti-TIF1-g (27%) autoantibodies.
The baseline cutaneous rashes in the adult DM and JDM cohort are described in Table 2 .
Adult DM
Baseline disease activity and damage in adult DM
Among adult DM patients, most had an active rash 89% (64/72), which included the classic DM rashes of Gottron changes and/or a heliotrope (50/72, 69%). The baseline mean (S.D.) cutaneous disease activity was 3.2 (2.46) on a 10 cm VAS, with the most common rashes including erythematous rashes without chronic changes of erosion or necrosis (44/72, 61%) and periungual capillary changes (44/72, 61%), followed by heliotrope rash and Gottron papules (41/72, 57% and 41/72, 57%, respectively).
Further details of the frequency of specific DM rashes at baseline and follow-up are noted in Table 2 . The baseline mean (S.D.) cutaneous damage (10 cm VAS) was 1.5 (2.02), (6) 3 (6) 11 (9) 12 (10) (32/67), P = 0.009. Among other individual rashes, a significant decrease in frequency was seen in erythroderma, erythematous rash without secondary changes of ulceration or necrosis, heliotrope, Gottron sign/papules, periungal erythema, diffuse alopecia and mechanics hands (Table 2 ). However, there was no significant improvement in cutaneous ulceration, panniculitis, erythematous rash with ulceration or necrosis or focal alopecia. Figure 1 graphically demonstrates this steady decline in the frequency of classic DM rashes after rituximab. A similar decline was seen in all of the other rashes that demonstrated a significant decrease in frequency (graphs not shown). The cutaneous disease activity score improved in most patients [67% (45/67)] by 50.5 cm on the 10 cm VAS, while 21% (14/67) were stable and 12% (8/67) worse (Fig. 2) . Among the damage variables, no major changes were seen in calcinosis, alopecia, cutaneous scarring or atrophy, poikiloderma and lipodystrophy ( Table 2 ). The mean (S.D.) VAS score on MDI was 1.49 (2.02) at baseline and significantly decreased to 0.96 (1.53) at the week 44 time point, P = 0.003. The median time to improvement of rash by 40% was week 16. There was no significant difference in the time to improvement among various DM autoantibody subsets or by DM autoantibody-positive patients compared with autoantibody-negative patients.
Effect of rituximab on cutaneous disease in adult DM
Patients in the rituximab early group demonstrated a trend for 20% relative improvement in their cutaneous disease activity score, faster than those in the rituximab late cohort (P < 0.052; Supplementary Fig. 1 ). Likewise, the rituximab early group also showed a trend for a more 
FIG. 1 Frequency of Gottron papules/sign and heliotrope in DM (A) and JDM (B)
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FIG. 2 Cutaneous disease activity at baseline and 36 weeks post-rituximab in DM patients (A) and JDM patients (B)
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Juvenile DM
Baseline disease activity and damage in JDM Among the JDM subset, all patients had an active rash (48/48), which included the classic features of Gottron and/or heliotrope seen in 96% (46/48) patients. The baseline mean (S.D.) cutaneous disease activity VAS was 3.27 (2.04), with the most common individual rashes being Gottron papules in 92% (44/48) followed by erythematous rashes without erosion or necrosis in 83% (40/48) and heliotrope rash in 69%. Further details of the frequency of other JDM rashes at baseline and follow-up are given in Table 2 . The baseline mean VAS (S.D.) cutaneous damage was 2.13 (2.34), with 46% of subjects having calcinosis, 23% with alopecia, 52% cutaneous scarring or atrophy, 23% poikiloderma and 13% with lipodystrophy.
Improvement in cutaneous rashes in JDM
There were significant improvements in the cutaneous disease activity, because the mean (S.D.) VAS reduced from 3.26 (2.04) at baseline to 1.56 (1.89) at week 36 (P < 0.0001) [median (interquartile range): from 2.9 (1.85.0) to 0.7 (0.22.7), P < 0.001]. The frequency of any JDM rash decreased from 100% (48/48) at baseline to 82% (36/44) at week 36 (P = 0.002). Likewise, the frequency of the classic JDM rashes (heliotrope or Gottron changes) decreased from 96% (46/48) to 64% (28/44) by study conclusion (P < 0.0001). Among individual rashes, a significant decrease was seen in cutaneous ulcerations, erythroderma, erythematous rash without ulceration or necrosis, heliotrope, Gottron sign/papules, periungual capillary changes and focal alopecia (Table 2 ). However, there was no significant improvement in panniculitis, erythematous rash with secondary changes of ulceration or necrosis, diffuse alopecia or mechanics hands. Figure 1 again graphically demonstrates the steady decline after rituximab in the frequency of the classic JDM rashes (heliotrope, Gottron papule/sign). A similar decline was seen in all other rashes that also significantly decreased (figure not shown). The cutaneous disease activity VAS score improved in most patients [75% (33/44) by 50.5], while it was stable in 14% (6/44) and worse in 11% (5/44) (Fig. 2) . Among the damage variables, no major changes were seen in calcinosis, alopecia, cutaneous scarring or atrophy, poikiloderma and lipodystrophy (Table 2) . Likewise, there was no statistical improvement in the VAS MDI, because it was 2.13 (2.34) at baseline and 1.98 (2.27) at the week 44 time point (P = 0.47). The median time to improvement of the rash by 40% occurred by week 12. There was no significant difference in time to improvement among various JDM autoantibody subsets or by JDM autoantibody-positive patients compared with autoantibody-negative patients.
Effect of rituximab on cutaneous disease in JDM
Patients in the rituximab early arm did not show a trend for 20% improvement in their cutaneous disease activity score faster than patients in the rituximab late arm (P = 0.5, Supplementary Fig. 1 ), but showed a weak trend for 40 and 60% relative improvement (P = 0.22 and P = 11, respectively).
Discussion
The RIM Trial was the first prospective, randomized, double-blind trial in myositis, the largest clinical trial ever performed in the inflammatory myopathies, and the first to combine adult and paediatric idiopathic inflammatory myopathy subjects [8] . We sought to assess the efficacy of rituximab on the cutaneous features of adult DM and JDM in a refractory cohort of myositis patients and used validated measures of disease activity and damage in adult and paediatric myositis patients [911, 13] . Our results showed significant overall improvement in cutaneous disease activity in adult DM and JDM patients after rituximab. Moreover, many rashes, such as Gottron changes, heliotrope and other erythematous rashes, improved in DM and JDM patients, including treatment-resistant cutaneous ulceration in the JDM subset. In adult DM, the cohort of subjects receiving rituximab early also demonstrated a trend for faster improvement in cutaneous disease activity compared with those receiving rituximab late, suggesting a possible rituximab-specific effect on cutaneous improvement. But in the JDM cohort, there was only a weak trend toward a faster improvement at 40 and 60% in those subjects receiving rituximab early, but none at 20% improvement. However, it is important to note that, collectively, the RIM Trial patients represent a cohort with generally refractory myositis, in whom therapy with glucocorticoids and, on average, less than two additional immunosuppressive agents had failed over the course of their disease. Autoantibody subgroups did not show a significant difference in terms of cutaneous improvement, but this could be attributable to small numbers of patients in each autoantibody subgroup. It is also of note that no major worsening in cumulative cutaneous damage resulted over the 44 week course of the RIM Trial. The pathogenesis of cutaneous disease in DM is not completely understood. Certainly, humoral immunity is implicated, with activation of the complement system leading to deposition of membrane attack complex in the capillaries. This leads to inflammation and necrosis of endothelial cells, thereby allowing activated T cells to migrate into muscle, causing ischaemia [16, 17] . It is possible that a similar mechanism is active in cutaneous manifestations of DM. Previous studies have shown more perivascular B lymphocytes than endomysial T lymphocytes in DM muscle, while skin lesions in DM show a predominance of T lymphocytes [18] . DM patients have also been found to have high serum concentrations of B-cell-activating factor, suggesting a more central role of the B cell [19, 20] . The characteristic features of a B cell antigen-driven autoimmune response in inflammatory myopathies include clonal expansion, class-switched somatic mutation and plasma cell maturation. In addition, B cells function as antigen presenting cells, co-stimulate T cells and secrete pro-inflammatory cytokines, thus making them a reasonable target in adult DM and JDM. Finally, the identification of several different autoantibodies in adult DM and JDM further supports the role of humoral immunity. Thus, our results demonstrate a significant improvement in the recalcitrant cutaneous lesions in DM after B cell depletion, supporting the role of the B cell in the pathogenesis of the cutaneous features of DM and JDM.
A potential limitation of the present study includes the post hoc nature of the analysis. However, we performed and presented results of all types of analyses that were performed, irrespective of results. Moreover, the analysis was driven by clinical questions relevant to the management of patients with DM rather than data mining. Another limitation inherent in the design of the RIM Trial is the difficulty in elucidating a true effect of rituximab compared with placebo, given the fact that both groups received rituximab within 8 weeks of each other. We attempted to overcome this limitation by assessing the time to 20, 40 and 60% improvement in the DM and JDM cohorts between the early vs late rituximab cohorts, but a lack of adequate power for subset analysis owing to smaller sample sizes limited the likelihood of finding a true effect, as well as a relatively short time difference (i.e. 8 weeks) between those subjects receiving rituximab early vs those receiving it later.
In conclusion, the refractory cutaneous rashes of DM and JDM improved in frequency as well as severity after rituximab in a large group of patients from the RIM Trial. However, it is difficult conclusively to attribute the efficacy directly to rituximab even though trends for more rapid improvement were observed in subjects receiving rituximab early compared with late.
